|
Synonyms: aldesleukin | interleukin-2 | Proleukin®
IL-2 is an approved drug (FDA (1992))
Compound class:
Endogenous peptide in human, mouse or rat
Comment: IL-2 and IL-15 are cytokines that share common biological effects, but also exhibit distinct, and sometimes competing, functions [6]. Recombinant IL-2 is used clinically with the generic name aldesleukin.
Abbas et al. (2018) have written a review of IL-2 biology and the progress that has been made in developing IL-2 therapeutics [1].
Species: Human
View more information in the IUPHAR Pharmacology Education Project: interleukin-2 |
| No information available. |
Summary of Clinical Use  |
| Aldesleukin is US FDA approved to treat metastatic renal cell carcinoma. The FDA has also granted orphan designation for non-Hodgkin's lymphoma (1998), primary immunodeficiency disease associated with T-cell defects (1989) and metastatic melanoma (1996). The EMA's orphan designation for renal cell carcinoma was withdrawn by the drug's sponsor. |
